Cargando…
Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension
AIM: To investigate the potential effect of inhibitors of phosphodiesterase-5 (PDE-5) for therapy of portal hypertension in liver cirrhosis. METHODS: In the rat model of thioacetamide-induced liver fibrosis/cirrhosis the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway was investigated....
Autores principales: | Schaffner, Denise, Lazaro, Adhara, Deibert, Peter, Hasselblatt, Peter, Stoll, Patrick, Fauth, Lisa, Baumstark, Manfred W, Merfort, Irmgard, Schmitt-Graeff, Annette, Kreisel, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189851/ https://www.ncbi.nlm.nih.gov/pubmed/30344420 http://dx.doi.org/10.3748/wjg.v24.i38.4356 |
Ejemplares similares
-
Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension
por: Kreisel, Wolfgang, et al.
Publicado: (2020) -
Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
por: Kreisel, Wolfgang, et al.
Publicado: (2021) -
Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up
por: Deibert, Peter, et al.
Publicado: (2018) -
Plasma Cyclic Guanosine Monophosphate Is a Promising Biomarker of Clinically Significant Portal Hypertension in Patients With Liver Cirrhosis
por: Sturm, Lukas, et al.
Publicado: (2022) -
Optogenetic manipulation of cyclic guanosine monophosphate to probe phosphodiesterase activities in megakaryocytes
por: Zhang, Yujing, et al.
Publicado: (2022)